Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Recursion Pharmaceuticals Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.86 (market cap $3.56B), while Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B). The key difference: GraniteShares 2x Long NVDA Daily ETF is the larger of the two by market cap, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NVDL | RXRX | |
|---|---|---|
Market Cap | $3.56B | $2.14B |
Volume | 9,740,643 | 30,789,535 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $6.79 |
52-Week Low | $21.76 | $2.84 |
Typical Hold Time | 15 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.335, down 5.65% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. Recent news highlights Nvidia's continued AI leadership and earnings beats, driving leveraged ETF interest. The ETF aims to deliver 2x daily returns of Nvidia stock, with technical analysis showing support at $36 and resistance at $38-39 levels.
The outlook remains tied to Nvidia's AI dominance and earnings performance. Investment opportunity exists through leveraged exposure to Nvidia's growth trajectory, though risks include daily reset leverage decay and Nvidia's high valuation. Recent SpaceX earnings have reshuffled AI chip trades, creating volatility. The ETF's performance depends on Nvidia maintaining its AI market leadership and execution.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
